Skip to main content

Table 2 Univariate analysis (upper column) and multivariate analysis (lower column) using Cox regression

From: Impact of tumor attachment to the pleura measured by a pretreatment CT image on outcome of stage I NSCLC treated with stereotactic body radiotherapy

Variables In-field control Locoregional control Freedom from distant metastasis Freedom from progression
P value HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI
Attachment status: broad attachment vs. others <0.01* 11.5 2.42-81.5 <0.01* 4.60 1.91-10.8 0.01* 3.02 1.22-7.19 <0.01* 3.78 1.87-7.40
Gender: female vs. male 0.89 1.11 0.15-5.20 0.29 0.57 0.16-1.54 0.57 1.29 0.49-3.03 0.54 0.79 0.35-1.62
Diagnosis: pathological vs. clinical 0.17 3.59 0.60-68.1 0.15 2.00 0.78-6.13 0.19 1.81 0.75-5.09 0.11 1.79 0.87-4.04
Tumor diameter (cm): per 1 cm increase <0.01* 3.71 1.47-9.72 <0.01* 2.25 1.30-3.83 <0.01* 2.01 1.19-3.33 <0.01* 2.02 1.32-3.07
Perfomance status: 0-1 vs. 2-3 0.97 0.96 0.15-18.5 0.88 1.09 0.36-4.71 0.38 1.81 0.52-11.3 0.48 1.42 0.56-4.81
SBRT dose (BED10): > 102 Gy10 vs. ≤ 102 Gy10 0.02* 0.13 0.01-0.79 0.59 1.25 0.54-3.05 0.88 0.94 0.45-2.02 0.77 0.90 0.47-1.75
Prescription: isocenter vs. D95 0.53 1.88 0.30-36.3 0.94 0.96 0.35-3.01 0.79 0.88 0.35-2.48 0.27 0.64 0.30-1.45
Attachment status: broad attachment vs. others 0.15 4.00 0.59-35.6 0.02* 3.08 1.15-8.27 0.19 1.93 0.70-5.29 0.01* 2.66 1.21-5.73
Tumor diameter (cm): per 1 cm increase 0.04* 3.65 1.00-14.1 0.12 1.67 0.86-3.10 0.09 1.68 0.91-3.00 0.06 1.59 0.96-2.55
SBRT dose (BED10): > 102 Gy10 vs. ≤ 102 Gy10 0.02* 0.10 0.01-0.75 n.s.    n.s.    n.s   
  1. Abbreviations: D95, doses covering 95% of the planning target volume; BED, biological effective dose; HR, hazard ratio; CI, confidence interval; n.s, not significant. *p < 0.05.